Follow
Jean-Pierre Routy
Jean-Pierre Routy
McGill University Health Centre
Verified email at mcgill.ca
Title
Cited by
Cited by
Year
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
L Trautmann, L Janbazian, N Chomont, EA Said, S Gimmig, B Bessette, ...
Nature medicine 12 (10), 1198-1202, 2006
19042006
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
N Chomont, M El-Far, P Ancuta, L Trautmann, FA Procopio, ...
Nature medicine 15 (8), 893-900, 2009
18902009
Antiretroviral-drug resistance among patients recently infected with HIV
SJ Little, S Holte, JP Routy, ES Daar, M Markowitz, AC Collier, RA Koup, ...
New England Journal of Medicine 347 (6), 385-394, 2002
15492002
High rates of forward transmission events after acute/early HIV-1 infection
BG Brenner, M Roger, JP Routy, D Moisi, M Ntemgwa, C Matte, JG Baril, ...
The Journal of infectious diseases 195 (7), 951-959, 2007
8692007
Towards an HIV cure: a global scientific strategy
Nature reviews Immunology 12 (8), 607-614, 2012
5932012
Programmed death-1–induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection
EA Said, FP Dupuy, L Trautmann, Y Zhang, Y Shi, M El-Far, BJ Hill, ...
Nature medicine 16 (4), 452-459, 2010
5732010
HIV-1 Viremia Prevents the Establishment of Interleukin 2–producing HIV-specific Memory CD4+ T Cells Endowed with Proliferative Capacity
SA Younes, B Yassine-Diab, AR Dumont, MR Boulassel, Z Grossman, ...
The Journal of experimental medicine 198 (12), 1909-1922, 2003
5422003
Interleukin-2 therapy in patients with HIV infection
INSIGHT–ESPRIT Study Group and SILCAAT Scientific Committee
New England Journal of Medicine 361 (16), 1548-1559, 2009
4202009
Peripheral blood CCR4+ CCR6+ and CXCR3+ CCR6+ CD4+ T cells are highly permissive to HIV-1 infection
A Gosselin, P Monteiro, N Chomont, F Diaz-Griffero, EA Said, S Fonseca, ...
The Journal of Immunology 184 (3), 1604-1616, 2010
3592010
HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation
ML Dion, JF Poulin, R Bordi, M Sylvestre, R Corsini, N Kettaf, A Dalloul, ...
Immunity 21 (6), 757-768, 2004
3212004
Wide variation in the multiplicity of HIV-1 infection among injection drug users
KJ Bar, H Li, A Chamberland, C Tremblay, JP Routy, T Grayson, C Sun, ...
Journal of virology 84 (12), 6241-6247, 2010
2692010
Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells
H Streeck, JS Jolin, Y Qi, B Yassine-Diab, RC Johnson, DS Kwon, ...
Journal of virology 83 (15), 7641-7648, 2009
2662009
Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection
BG Brenner, JP Routy, M Petrella, D Moisi, M Oliveira, M Detorio, B Spira, ...
Journal of virology 76 (4), 1753-1761, 2002
2632002
CD4: CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV‐positive patients
W Lu, V Mehraj, K Vyboh, W Cao, T Li, JP Routy
Journal of the International AIDS Society 18 (1), 20052, 2015
2592015
Interleukin-7 promotes HIV persistence during antiretroviral therapy
C Vandergeeten, R Fromentin, S DaFonseca, MB Lawani, I Sereti, ...
Blood, The Journal of the American Society of Hematology 121 (21), 4321-4329, 2013
2592013
Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells
S Reiss, AE Baxter, KM Cirelli, JM Dan, A Morou, A Daigneault, ...
PloS one 12 (10), e0186998, 2017
2522017
Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide–based 3-or 4-drug regimen for maintenance of …
J Van Wyk, F Ajana, F Bisshop, S De Wit, O Osiyemi, J Portilla Sogorb, ...
Clinical Infectious Diseases 71 (8), 1920-1929, 2020
2432020
Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized …
Y Levy, I Sereti, G Tambussi, JP Routy, JD Lelievre, JF Delfraissy, ...
Clinical infectious diseases 55 (2), 291-300, 2012
2372012
Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
H Salomon, MA Wainberg, B Brenner, Y Quan, D Rouleau, P Coté, ...
Aids 14 (2), F17-F23, 2000
2322000
Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo
CC Nixon, M Mavigner, GC Sampey, AD Brooks, RA Spagnuolo, ...
Nature 578 (7793), 160-165, 2020
2282020
The system can't perform the operation now. Try again later.
Articles 1–20